Labetuzumab govitecan

Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC) . Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3].

Product Specifications

CAS Number

[1469876-18-3]

Product Name Alternative

IMMU 130; hMN-14-SN-38

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/labetuzumab-govitecan.html

Purity

98.66

Solubility

10 mM in DMSO

Smiles

[Labetuzumabgovitecan]

Molecular Weight

154000 (average)

References & Citations

[1]Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35 (29) :3338-3346. |[2]Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12 (6) :1836-47. |[3]Criscitiello C, et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14 (1) :20.